Importantly, the percentage of CD38+HLA-DR+CD8+ cells was significantly increased in patients with recurrent glioma (newly = 8.2 ± 1%; recurrent = 12.5 ± 2%; Figure 2E); high-grade glioma (GIII and/or GIV), both in the PBMCs (GII = 7.6 ± 2%, GIII = 10.1 ± 2%, and GIV = 12.9 ± 2%; Figure 2F) and TILs (GII = 2.0 ± 1%, GIII = 24.5 ± 4%, and GIV = 31.6 ± 2%; Figure 2G). This evidence concerns the gene CD38 and central nervous system cancer.